Relationship between vitreous levels of matrix metalloproteinases and vascular endothelial growth factor in proliferative diabetic retinopathy

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Abu El Asrar, Ahmed M ^a   Mohammad, Ghulam ^a   Nawaz, Mohd Imtiaz ^a   Siddiquei, Mohammad Mairaj ^a   Van Den Eynde, Kathleen ^b   Mousa, Ahmed ^a   De Hertogh, Gert ^b   Opdenakker, Ghislain ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETIC RETINOPATHY; HUMANS; MATRIX METALLOPROTEINASES; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 84893652167     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085857     Document Type: Article

References (34)

1. Deryugina EI, Quigley JP (2010) Pleiotropic roles of matrix metalloproteinases in tumor angiongenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta 1803: 103-120. doi:10.1016/j. bbamcr.2009.09.017. PubMed: 19800930.
2. Spranger J, Pfeiffer AF (2001) New concepts in pathogenesis and treatment of diabetic retinopathy. Exp Clin Endocrinol Diabetes 109 Suppl 2: S438-S450. doi:10.1055/s-2001-18601. PubMed: 11460590. (Pubitemid 32586079)
3. Hawinkels LJ, Zuidwijk K, Verspaget HW, de Jonge-Muller ES, van Duijn W et al. (2008) VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer 44: 1904-1913. doi:10.1016/j.ejca. 2008.06.031. PubMed: 18691882.
4. Ebrahem Q, Chaurasia SS, Vasanji A, Qi JH, Klenotic PA et al. (2010) Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Am J Pathol 176: 496-503. doi:10.2353/ajpath.2010.080642. PubMed: 19948826.
5. Hu J, Van den Steen PE, Sang QX, Opdenakker G (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6: 480-498. doi:10.1038/nrd2308. PubMed: 17541420. (Pubitemid 47064570)
6. Descamps FJ, Martens E, Kangave D, Struyf S, Geboes K et al. (2006) The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage. Exp Eye Res 83: 401-407. doi:10.1016/j.exer.2006. 01.017. PubMed: 16643893.
7. Noda K, Ishida S, Inoue M, Obata K, Oguchi Y et al. (2003) Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 44: 2163-2170. doi:10.1167/iovs.02-0662. PubMed: 12714657. (Pubitemid 36520313)
8. Jin M, Kashiwagi K, Iizuka Y, Tanaka Y, Imai M et al. (2001) Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 21: 28-33. doi:10.1097/00006982-200102000-00005. PubMed: 11217926. (Pubitemid 32151759)
9. Kosano H, Okano T, Katsura Y, Noritake M, Kado S et al. (1999) ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci 64: 2307-2315. doi:10.1016/S0024-3205(99)00184-8. PubMed: 10374894. (Pubitemid 29274224)
10. Vandooren J, Geurts N, Martens E, Van den Steen PE, Opdenakker G (2013) Zymography methods for visualizing hydrolytic enzymes. Nat Methods 10:211: 220. PubMed: 23443633.
11. Paemen L, Martens E, Masure S, Opdenakker G (1995) Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site RLISA and inhibition of enztmatic activity. Eur J Biochem 234: 759-765. doi:10.1111/j.1432-1033.1995.759-a.x. PubMed: 8575432. (Pubitemid 26024332)
12. Pulukuri SM, Rao JS (2008) Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int J Oncol 32: 757-765. PubMed: 18360703. (Pubitemid 351780586)
13. Goerge T, Barg A, Schnaeker EM, Poppelmann B, Shpacovitch V et al. (2006) Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res 66: 7766-7774. doi:10.1158/0008-5472.CAN-05-3897. PubMed: 16885380. (Pubitemid 44289237)
14. Blackburn JS, Rhodes CH, Coon Cl, Brinckerhoff CE (2007). RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res 67:10849-10858 (Pubitemid 350145914)
15. Eck SM, Hoopes PJ, Petrella BL, Coon Cl, Brinckerhoff CE (2009). Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat 116:79-90
16. Blackburn JS, Brinckerhoff CE (2008) Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis. Am J Pathol 173: 1736-1746. doi:10.2353/ajpath.2008. 080512. PubMed: 18988801.
17. Pufe T, Harde V, Petersen W, Goldring MB, Tillmann B et al. (2004) Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes. J Pathol 202: 367-374. doi:10.1002/path.1527. PubMed: 14991903. (Pubitemid 38325247)
18. Wang H, Keiser JA (1998) Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res 83: 832-840. doi:10.1161/01.RES.83.8.832. PubMed: 9776730. (Pubitemid 28489080)
19. Steenport M, Khan KM, Du B, Barnhard SE, Dannenberg AJ et al. (2009) Matrix metalloproteinase (MMP)-1 and MMP-3 induce macrophage MMP-9: evidence for the role of TNF-alpha and cyclooxygenase-2. J Immunol 183: 8119-8127. doi:10.4049/jimmunol.0901925. PubMed: 19923455.
20. Sier CF, Hawinkels LJ, Zijlmans HJ, Zuidwijk K, de Jonge-Muller ES et al. (2008) Endothelium specific matrilysin (MMP-7) expression in human cancers. Matrix Biol 27: 267-271. PubMed: 18023162. (Pubitemid 351384767)
21. Huo N, Ichikawa Y, Kamiyama M, Ishikawa T, Hamaguchi Y et al. (2002) MMP-7 (matrilysin) accelerated growth of human umbilical vein endothelial cells. Cancer Lett 177: 95-100. doi:10.1016/S0304-3835(01)00772-8. PubMed: 11809536. (Pubitemid 34102404)
22. Ito TK, Ishii G, Saito S, Yano K, Hoshino A et al. (2009) Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells. Blood 113: 2363-2369. doi:10.1182/blood-2008-08-172742. PubMed: 18974372.
23. Vandooren J, Van den Steen PE, Opdenakker G (2013) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol 48: 222-272. doi:10.3109/10409238.2013. 770819. PubMed: 23547785.
24. Shibuya M (2006) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39: 469-478. doi:10.5483/BMBRep.2006.39.5.469. PubMed: 17002866.
25. Alexandrakis MG, Sfiridaki A, Miyakis S, Pappa C, Kandika E et al. (2007) Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma. Clin Chim Acta, 379: 379-2:31-35. PubMed: 17234170.
26. Zaman K, Driscoll R, Hahn D, Werffeli P, Goodman SL et al. (2006) Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. Int J Cancer 118: 755-764. doi:10.1002/ijc.21408. PubMed: 16114015. (Pubitemid 43076028)
27. Kim KS, Choi HM, Lee YA, Choi IA, Lee SH et al. (2011) Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int 31: 543-547. doi:10.1007/s00296-010-1592-1. PubMed: 20665024.
28. Hollborn M, Stathopoulos C, Steffen A, Wiedemann P, Kohen L et al. (2007) Positive feedback regulation between MMP-9 and VEGF in human RPE cells. Invest Ophthalmol Vis Sci 48: 4360-4367. doi:10.1167/iovs.06-1234. PubMed: 17724228. (Pubitemid 351261070)
29. Ahn GO, Brown JM (2008) Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13: 193-205. doi:10.1016/j.ccr.2007.11.032. PubMed: 18328424.
30. Bekes EM, Schweighofer B, Kupriyanova TA, Zajac E, Ardi VC et al. (2011) Tumor-recruited neutrophils and neuthrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol 179: 1455-1470. doi:10.1016/j.ajpath.2011.05.031. PubMed: 21741942.
31. Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP (2007) Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci U S A 104: 20262-20267. doi:10.1073/pnas.0706438104. PubMed: 18077379.
32. Ardi VC, Van den Steen PE, Opdenakker G, Schweighofer B, Deryugina EI et al. (2009) Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. J Biol Chem 284: 25854-25866. doi:10.1074/jbc.M109.033472. PubMed: 19608737.
33. Shirasawa M, Arimura N, Otsuka H, Sonoda S, Hashiguchi T et al. (2011) Intravitreous VEGF-A in eyes with massive vitreous hemorrhage. Graefes Arch Clin Exp Ophthalmol 249: 1805-1810. doi:10.1007/s00417-011-1795-5. PubMed: 21853228.
34. Abu El-Asrar AM, Nawaz MI, Siddiquei MM, Al-Kharashi AS, Kangave D, et al. (2013). High-mobility group box-1 induces decreased brain-derived neurotrophic factor-mediated neuroprotection in the diabetic retina. Mediators Inflamm 2013:863036 Doi: 10.1155/2013/863036.